Cell and Gene Therapy Today—March 5, 2026
This is a weekly update in gene and cell therapy, covering key regulatory…
Lucid Diligence Brief: Gilead to acquire Arcellx (anito-cel)
Lucid Diligence Brief: Gilead to acquire Arcellx (anito-cel) Professional…
Cell and Gene Therapy Today—February 19, 2026
This week's update in gene and cell therapy covers notable developments…
Cell and Gene Therapy Today—February 5, 2026
This week's Cell and Gene Therapy updatehighlights key regulatory actions,…
Lucid Diligence Brief: AstraZeneca buys remaining China rights to AbelZeta’s GPC3-armored CAR-T
Lucid Diligence Brief: AstraZeneca buys remaining China rights to AbelZeta’s…
Lucid Diligence Brief: Cytotheryx $60 million Series A in liver cell therapy
Lucid Diligence Brief: Cytotheryx $60 million Series A in liver cell therapy…
Neuroscience Today—January 14, 2026
Today's neuroscience weekly update spotlights major advances spanning cell and…
Lucid Diligence Brief: Vyriad $25M Series B to take in-vivo CAR-T into clinic
Lucid Diligence Brief: Vyriad $25M Series B to take in-vivo CAR-T into clinic…
Cell and Gene Therapy Today—December 18, 2025
This week’s Cell & Gene Therapy update highlights major developments,…
Lucid Diligence Brief: Imugene onCARlytics Carteyva collaboration
Lucid Diligence Brief: Imugene onCARlytics Carteyva collaboration Professional…
Lucid Diligence Brief: Aspen Neuroscience $115M Series C
Lucid Diligence Brief: Aspen Neuroscience $115M Series C Professional audiences…
Lucid Diligence Brief: Tempest Therapeutics and Factor Bioscience dual-CAR T deal
Lucid Diligence Brief: Tempest Therapeutics and Factor Bioscience dual-CAR T…